We are offering the following trials in partnership with the Seattle Cancer Care Alliance (SCCA):
- Combined Targeted Therapies for Triple Negative Advanced Breast Cancer – A Phase II Trial of Weekly Nab-Paclitaxel (Abraxane) and Bevacizumab (Avastin) Followed by Maintenance Targeted Therapy With Bevacizumab (Avastin) and Erlotinib (Tarceva)
Contact: Christine Reed, 541-706-6592 or email@example.com
Location: Bend, Oregon (Central Oregon)
For general inquiries, please contact the BMC Research Department at firstname.lastname@example.org or 877-692-8338.